Journal of neurosurgery
-
Journal of neurosurgery · Jan 2023
ReviewCost-effectiveness analysis of endovascular treatment with or without intravenous thrombolysis in acute ischemic stroke.
Intravenous (IV) recombinant tissue plasminogen activator (r-tPA) may not provide additional benefit in terms of functional outcomes in patients with acute ischemic stroke (AIS) who undergo endovascular treatment (EVT). In this context, the cost-effectiveness of EVT alone compared with its application following IV r-tPA has not been evaluated. ⋯ EVT alone appears to be more cost-effective compared with EVT and IV r-tPA for the treatment of AIS patients presenting within 4.5 hours of symptom onset.